SCHEMBL4588807

SCHEMBL4588807

NCCCC[C@H](NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](N)CO)C(=O)[O-].NCCCC[C@H](NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](N)CO)C(=O)[O-].[Mn+2]

nearest known ligand 0.41

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
SLC15A2 Q16348 1/20 0.41
GHSR Q92847 5/20 0.36
OPRK1 P41145 1/20 0.32
PSMB1 P20618 1/20 0.32
PSMB8 P28062 1/20 0.32
PSMB9 P28065 1/20 0.32
PSMB5 P28074 1/20 0.32
PSMB10 P40306 1/20 0.32
PSMB2 P49721 1/20 0.32
NMT2 O60551 1/20 0.32
NMT1 P30419 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2813367 0.98 SLC15A2 (0.41) SLC15A2GHSROPRK1PSMB1PSMB8
SCHEMBL5598605 0.90 SLC15A2 (0.49) SLC15A2GHSR
SCHEMBL5598601 0.90 SLC15A2 (0.49) SLC15A2GHSR
SCHEMBL4587314 0.89 SLC15A2 (0.39) SLC15A2GHSROPRK1
SCHEMBL2813363 0.89 SLC15A2 (0.48) SLC15A2GHSR
SCHEMBL4588260 0.89 SLC15A2 (0.42) SLC15A2GHSR
SCHEMBL4588801 0.89 SLC15A2 (0.48) SLC15A2GHSR
SCHEMBL9488944 0.89 SLC15A2 (0.40) SLC15A2GHSROPRK1PSMB1PSMB8
SCHEMBL5792595 0.88 SLC15A2 (0.44) SLC15A2GHSROPRK1NMT2NMT1
SCHEMBL4587124 0.88 SLC15A2 (0.54) SLC15A2GHSRNMT2NMT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080255032-A1 METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING AGING OR PHOTODAMAGED SKIN PROCYTE CORPORATION (US) 2008-10-16 US disclosed
US-7384916-B2 Methods and compositions for preventing and treating aging or photodamaged skin PROCYTE CORPORATION (US) 2008-06-10 US disclosed
US-20060246029-A1 Methods and compositions for preventing and treating aging or photodamaged skin PROCYTE CORPORATION (US) 2006-11-02 US disclosed
US-20060018851-A1 Methods and compositions for preventing and treating hyperpigmentation of skin PROCYTE CORPORATION (US) 2006-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060246029-A1 Methods and compositions for preventing and treating aging or photodamaged skin RBP1, RBP4, SOD1 SLC15A2 2656/4885GHSR 1411/4885OPRK1 4363/4885
US-20060018851-A1 Methods and compositions for preventing and treating hyperpigmentation of skin RBP1, RBP4, MC1R SLC15A2 1582/4885GHSR 748/4885OPRK1 2506/4885
US-20080255032-A1 METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING AGING OR PHOTODAMAGED SKIN RBP1, RBP4, SOD1 SLC15A2 2656/4885GHSR 1411/4885OPRK1 4363/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.